ALSO NOTED: Celebrex cancer study on; FDA rejects Xinlay; and much more...

> Despite parallels to the Vioxx study which damaged Merck, Pfizer has given the go ahead for the M.D. Anderson Cancer Center to study Celebrex's potential value as a cancer treatment. Story

> WebMD Health Holdings (the website businesses which are being spun off from the newly renamed Emdeon) priced shares in its IPO in the range of $13.50 to $15.50 per share. Story (Wall Street Journal sub. req.)

> Expect to hear more about this story: Louisiana officials say they have hired emergency management specialist Kenyon directly after FEMA was unable to negotiate a contract. Story

> An FDA panel has rejected Abbott pharmaceuticals' experimental prostate cancer drug Xinlay. Story

> Med Tech: Could a Department of Bionic Medicine be next? A look at trends in high-tech medical implants which are transforming the potential of the human body. Story

> Five months after the HIPAA Security rule went into effect, many healthcare providers are still not in compliance, their CIOs admit. Story

> Testimony begins this morning in the second Vioxx trial. Story

> Philips Medical Systems said it has signed a $70 million deal with Alberta's Capital Health to provide diagnostic imaging equipment. Release

And Finally... Microsoft decides that RHIOs are a bandwagon that it wants to climb aboard, and it's going to hand out awards to prove it. Story

Post a comment